 |
 |
     |
|
| Creating the next generation of cancer treatments |
 |
|
 |
 AR-42AR-42 is an orally available, broad-spectrum deactylation inhibitor of both histone and non-histone proteins which play an important role in the regulation of gene expression, cell growth and survival. In preclinical studies, AR-42 has demonstrated greater potency and activity in solid and liquid tumors when compared to vorinostat (also known as SAHA and marketed as Zolinza® by Merck) and other deacetylase inhibitors. These data demonstrate the potent and differentiating activity of AR-42. Additionally, pre-clinical findings showed that AR-42 potently and selectively inhibits leukemic stem cells in acute myeloid leukemia, or AML. AR-42 is currently being studied in an investigator-initiated Phase I/IIa clinical study in adult patients with relapsed or refractory multiple myeloma, chronic lymphocytic leukemia or lymphoma. CLINICAL PROGRAM For information about the current clinical program, please go to [ LINK HERE ] | | 
Arno Therapeutics, Inc. |
©2011 Arno Therapeutics, Inc. | Privacy Policy |